A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 117 participants.

Also called NCT07192952

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 117 participants (planned count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07192952
  • EU CT 2024-519830-22-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, Germany, Greece, Hungary, Israel, Italy, Mexico, Poland, Portugal, South Korea, Spain, Sweden, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07192952. Allocation not applicable; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2030-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Acronym
FIORELLO
Condition
Left Ventricular Systolic Dysfunction
Condition
Heart Failure (Pediatric)
Intervention (Drug)
Finerenone (Kerendia, BAY94-8862)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct07192952
Content hash
1d06945bf64dbc2084bdb636a3d65ffd517ff304273029c0ad831cd214d414ee